The bioenergetic signature of isogenic colon cancer cells predicts the cell death response to treatment with 3-bromopyruvate, iodoacetate or 5-fluorouracil

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Sánchez Aragó, María ^a   Cuezva, José M ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BROMOPYRUVIC ACID; FLUOROURACIL; IODOACETIC ACID; LACTIC ACID; UNCLASSIFIED DRUG; GLUTAMINE; PYRUVIC ACID DERIVATIVE;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOENERGETIC SIGNATURE; BIOLUMINESCENCE; CANCER CELL; CELL DEATH; CELL ENERGY; COLON CANCER; CONTROLLED STUDY; DRUG RESPONSE; ENERGY METABOLISM; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOGENIC COLON CANCER CELL; MALE; MOUSE; NONHUMAN; PREDICTION; PROTEIN ANALYSIS; TUMOR REGRESSION; WESTERN BLOTTING; CELL STRAIN HCT116; COLON TUMOR; DRUG EFFECT; METABOLISM; PATHOLOGY; REMISSION; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; BLOTTING, WESTERN; CELL DEATH; COLONIC NEOPLASMS; ENERGY METABOLISM; FLUOROURACIL; GLUTAMINE; HCT116 CELLS; HUMANS; IODOACETATES; PYRUVATES; REMISSION INDUCTION; SIGNAL TRANSDUCTION;

EID: 79551685039     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-19     Document Type: Article

References (37)

1. Gellad ZF, Provenzale D. Colorectal cancer: national and international perspective on the burden of disease and public health impact. Gastroenterology 2010, 138:2177-2190. 10.1053/j.gastro.2010.01.056, 20420954.
2. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N. Colorectal cancer. Lancet 2010, 375:1030-1047. 10.1016/S0140-6736(10)60353-4, 20304247.
3. Cuezva JM, Ortega AD, Willers I, Sanchez-Cenizo L, Aldea M, Sanchez-Arago M. The tumor suppressor function of mitochondria: Translation into the clinics. Biochim Biophys Acta 2009, 1792:1145-1158.
4. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008, 7:11-20. 10.1016/j.cmet.2007.10.002, 18177721.
5. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13:472-482. 10.1016/j.ccr.2008.05.005, 18538731.
6. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010, 10:267-277. 10.1038/nrc2817, 20300106.
7. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25:4633-4646. 10.1038/sj.onc.1209597, 16892078.
8. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783. 10.1038/nature07733, 2778612, 19194462.
9. Lopez-Rios F, Sanchez-Arago M, Garcia-Garcia E, Ortega AD, Berrendero JR, Pozo-Rodriguez F, Lopez-Encuentra A, Ballestin C, Cuezva JM. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res 2007, 67:9013-9017. 10.1158/0008-5472.CAN-07-1678, 17909002.
10. Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaria G, Kim H, Zapata JM, Marusawa H, Chamorro M, Reed JC. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 2002, 62:6674-6681.
11. Sanchez-Arago M, Chamorro M, Cuezva JM. Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis 2010, 31:567-576. 10.1093/carcin/bgq012, 20080835.
12. Bi X, Lin Q, Foo TW, Joshi S, You T, Shen HM, Ong CN, Cheah PY, Eu KW, Hew CL. Proteomic analysis of colorectal cancer reveals alterations in metabolic pathways: mechanism of tumorigenesis. Mol Cell Proteomics 2006, 5:1119-1130. 10.1074/mcp.M500432-MCP200, 16554294.
13. Chen J, Kahne T, Rocken C, Gotze T, Yu J, Sung JJ, Chen M, Hu P, Malfertheiner P, Ebert MP. Proteome analysis of gastric cancer metastasis by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of metastasis-related proteins. J Proteome Res 2004, 3:1009-1016. 10.1021/pr049916l, 15473690.
14. Cuezva JM, Chen G, Alonso AM, Isidoro A, Misek DE, Hanash SM, Beer DG. The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinogenesis 2004, 25:1157-1163. 10.1093/carcin/bgh113, 14963017.
15. He QY, Chen J, Kung HF, Yuen AP, Chiu JF. Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. Proteomics 2004, 4:271-278. 10.1002/pmic.200300550, 14730689.
16. Isidoro A, Casado E, Redondo A, Acebo P, Espinosa E, Alonso AM, Cejas P, Hardisson D, Fresno Vara JA, Belda-Iniesta C, et al. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 2005, 26:2095-2104. 10.1093/carcin/bgi188, 16033770.
17. Isidoro A, Martinez M, Fernandez PL, Ortega AD, Santamaria G, Chamorro M, Reed JC, Cuezva JM. Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem J 2004, 378:17-20. 10.1042/BJ20031541, 1223948, 14683524.
18. Unwin RD, Craven RA, Harnden P, Hanrahan S, Totty N, Knowles M, Eardley I, Selby PJ, Banks RE. Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 2003, 3:1620-1632. 10.1002/pmic.200300464, 12923786.
19. Lin PC, Lin JK, Yang SH, Wang HS, Li AF, Chang SC. Expression of beta-F1-ATPase and mitochondrial transcription factor A and the change in mitochondrial DNA content in colorectal cancer: clinical data analysis and evidence from an in vitro study. Int J Colorectal Dis 2008, 23:1223-1232. 10.1007/s00384-008-0539-4, 18769884.
20. Ortega AD, Sala S, Espinosa E, Gonzalez-Baron M, Cuezva JM. HuR and the bioenergetic signature of breast cancer: a low tumor expression of the RNA-binding protein predicts a higher risk of disease recurrence. Carcinogenesis 2008, 29:2053-2061. 10.1093/carcin/bgn185, 18687667.
21. Shin YK, Yoo BC, Chang HJ, Jeon E, Hong SH, Jung MS, Lim SJ, Park JG. Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 2005, 65:3162-3170.
22. Li RJ, Zhang GS, Chen YH, Zhu JF, Lu QJ, Gong FJ, Kuang WY. Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance. Ann Oncol 2010, 7:1506-1514.
23. Hernlund E, Hjerpe E, Avall-Lundqvist E, Shoshan M. Ovarian carcinoma cells with low levels of beta-F1-ATPase are sensitive to combined platinum and 2-deoxy-D-glucose treatment. Mol Cancer Ther 2009, 8:1916-1923. 10.1158/1535-7163.MCT-09-0179, 19567816.
24. Hernlund E, Ihrlund LS, Khan O, Ates YO, Linder S, Panaretakis T, Shoshan MC. Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int J Cancer 2008, 123:476-483. 10.1002/ijc.23525, 18452174.
25. Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 2002, 62:3909-3913.
26. Bickis IJ, Quastel JH. Effects of Metabolic Inhibitors on Energy Metabolism of Ehrlich Ascites Carcinoma Cells. Nature 1965, 205:44-46. 10.1038/205044a0, 14283130.
27. Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Vossen JA, Tchernyshyov I, Cole RN, Syed LH, Rao PP, Ota S, Vali M. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res 2009, 29:4909-4918.
28. Pigault C, Follenius-Wund A, Schmutz M, Freyssinet JM, Brisson A. Formation of two-dimensional arrays of annexin V on phosphatidylserine-containing liposomes. J Mol Biol 1994, 236:199-208. 10.1006/jmbi.1994.1129, 8107105.
29. Jaattela M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 2004, 23:2746-2756. 10.1038/sj.onc.1207513, 15077138.
30. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004, 18:1272-1282. 10.1101/gad.1199904, 420353, 15145826.
31. Munoz-Pinedo C, Ruiz-Ruiz C, Ruiz de Almodovar C, Palacios C, Lopez-Rivas A. Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signaling complex formation and apical procaspase-8 processing. J Biol Chem 2003, 278:12759-12768. 10.1074/jbc.M212392200, 12556444.
32. Acebo P, Giner D, Calvo P, Blanco-Rivero A, Ortega AD, Fernandez PL, Roncador G, Fernandez-Malave E, Chamorro M, Cuezva JM. Cancer abolishes the tissue type-specific differences in the phenotype of energetic metabolism. Transl Oncol 2009, 2:138-145. 2730139, 19701498.
33. Santamaria G, Martinez-Diez M, Fabregat I, Cuezva JM. Efficient execution of cell death in non-glycolytic cells requires the generation of ROS controlled by the activity of mitochondrial H+-ATP synthase. Carcinogenesis 2006, 27:925-935. 10.1093/carcin/bgi315, 16361271.
34. Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ, Capaldi RA. Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res 2004, 64:985-993. 10.1158/0008-5472.CAN-03-1101, 14871829.
35. Tomiyama A, Serizawa S, Tachibana K, Sakurada K, Samejima H, Kuchino Y, Kitanaka C. Critical role for mitochondrial oxidative phosphorylation in the activation of tumor suppressors Bax and Bak. J Natl Cancer Inst 2006, 98:1462-1473. 10.1093/jnci/djj395, 17047195.
36. Matsuyama S, Xu Q, Velours J, Reed JC. The Mitochondrial F0F1-ATPase proton pump is required for function of the proapoptotic protein Bax in yeast and mammalian cells. Mol Cell 1998, 1:327-336. 10.1016/S1097-2765(00)80033-7, 9660917.
37. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9:425-434. 10.1016/j.ccr.2006.04.023, 16766262.